TD Cowen upgraded shares of Standard BioTools (NASDAQ:LAB - Free Report) to a strong-buy rating in a report published on Thursday,Zacks.com reports.
Standard BioTools Price Performance
NASDAQ LAB traded down $0.01 during trading hours on Thursday, hitting $1.23. The company had a trading volume of 274,763 shares, compared to its average volume of 1,910,986. The firm's 50 day moving average is $1.14 and its 200 day moving average is $1.26. The company has a market capitalization of $465.28 million, a price-to-earnings ratio of -3.50 and a beta of 1.54. Standard BioTools has a fifty-two week low of $0.92 and a fifty-two week high of $2.41.
Hedge Funds Weigh In On Standard BioTools
A number of large investors have recently bought and sold shares of the business. Takeda Pharmaceutical Co. Ltd. acquired a new position in Standard BioTools in the fourth quarter worth approximately $29,000. Two Sigma Securities LLC purchased a new position in Standard BioTools during the 4th quarter worth approximately $30,000. Jump Financial LLC purchased a new position in Standard BioTools during the 1st quarter worth approximately $26,000. Aquatic Capital Management LLC purchased a new position in Standard BioTools during the 4th quarter worth approximately $45,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd grew its position in Standard BioTools by 115.6% during the 1st quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 27,119 shares of the company's stock worth $29,000 after purchasing an additional 14,541 shares in the last quarter. Institutional investors own 53.74% of the company's stock.
About Standard BioTools
(
Get Free Report)
Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.
See Also
Before you consider Standard BioTools, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Standard BioTools wasn't on the list.
While Standard BioTools currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access